drugset / Trial / NCT04415749
NasoShield in Healthy Adults to Study Safety and Immunogenicity
Phase 1
Completed
43 enrolled
Altimmune, Inc.
Biomedical Advanced Research and Development Authority · collab
RandomizedParallel-groupDouble-blindPrevention
Summary
The purpose of this study is to evaluate the safety for up to two doses of NasoShield, to determine if antibodies that protect against anthrax are formed after treatment with NasoShield, and to determine whether the formation of these antibodies are affected by different positions of administration.
Timeline
- Start
- 2020-06-15
- Primary completion
- 2021-03-15
- Completion
- 2021-03-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | NasoShield | Vaccine | 1e+11 vg | — |
Indications
No indication recorded.